We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

70 hedge funds and large institutions have $251M invested in Progenics Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

3% less capital invested

Capital invested by funds: $258M → $251M (-$6.61M)

16% less funds holding

Funds holding: 83 → 70 (-13)

64% less call options, than puts

Call options by funds: $484K | Put options by funds: $1.33M

65% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 20

Holders
70
Holders Change
-13
Holders Change %
-15.66%
% of All Funds
2.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
23
Reduced
22
Closed
20
Calls
$484K
Puts
$1.33M
Net Calls
-$843K
Net Calls Change
-$346K

Top Buyers

Rank Fund Capital Flow
1
PFC
Phocas Financial Corp
California
+$2.75M
2
BC
Broadfin Capital
New York
+$2.29M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$545K
4
JG
Jefferies Group
New York
+$532K
5
BIT
BlackRock Institutional Trust
California
+$506K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$11.4M
2
HCMT
Highland Capital Management (Texas)
Texas
-$3.17M
3
Morgan Stanley
Morgan Stanley
New York
-$1.82M
4
BIM
Bogle Investment Management
Massachusetts
-$1.7M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
51
American International Group
New York
$211K +$23.3K +5,301 +15%
DekaBank Deutsche Girozentrale
52
DekaBank Deutsche Girozentrale
Germany
$189K +$4.4K +1,000 +3%
GT
53
Glenmede Trust
Pennsylvania
$183K – – –
ProShare Advisors
54
ProShare Advisors
Maryland
$166K -$123K -27,855 -47%
Nomura Holdings
55
Nomura Holdings
Japan
$164K +$135K +30,800 New
DSC
56
Duncker Streett & Co
Missouri
$131K – – –
Citigroup
57
Citigroup
New York
$127K +$44K +9,992 +72%
Two Sigma Investments
58
Two Sigma Investments
New York
$123K +$102K +23,109 New
PAM
59
Panagora Asset Management
Massachusetts
$116K – – –
CHAM
60
Clear Harbor Asset Management
Connecticut
$107K +$88K +20,000 New
FM
61
Family Management
New York
$69K – – –
Prudential Financial
62
Prudential Financial
New Jersey
$67K -$7.48K -1,700 -12%
AL
63
Airain Ltd
Guernsey
$66K -$50.3K -11,434 -48%
U
64
UBS
Switzerland
$29K -$32.4K -7,360 -57%
Fifth Third Bancorp
65
Fifth Third Bancorp
Ohio
$27K -$2.2K -500 -9%
PNC Financial Services Group
66
PNC Financial Services Group
Pennsylvania
$24K – – –
BlackRock
67
BlackRock
New York
$8K – – –
BNP Paribas Financial Markets
68
BNP Paribas Financial Markets
France
$4.12K -$65.5K -14,883 -95%
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
$2K -$3.64K -827 -73%
Manulife (Manufacturers Life Insurance)
70
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$248 +$13.8K +3,126 +7%
BIM
71
Bogle Investment Management
Massachusetts
– -$1.7M -338,411 Closed
Renaissance Technologies
72
Renaissance Technologies
New York
– -$1.41M -280,100 Closed
HCM
73
Highbridge Capital Management
New York
– -$1.34M -266,719 Closed
SGAM
74
Smith Group Asset Management
Texas
– -$923K -183,820 Closed
PA
75
Perceptive Advisors
New York
– -$849K -169,068 Closed
1 2
3
4

PGNX Hedge Fund Activity: Q4 2013 in Review

70 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2013, worth a combined $251M — down 2.6% from $258M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of PGNX and 7 opened new positions — a net loss of 13 holders — while 22 trimmed existing stakes and 23 added.

The largest buyer was Phocas Financial Corp, opening a new position worth an estimated $2.75M. The largest seller was Fidelity Investments, cutting an estimated $11.4M.

  • 70 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2013, down from 83 in Q3 2013.
  • Funds reported $251M of Progenics Pharmaceuticals Inc stock for Q4 2013, down 2.6% quarter-over-quarter.
  • 7 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2013 and 20 closed out, a net change of -13 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2013 was Phocas Financial Corp, an estimated $2.75M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2013 was Fidelity Investments, an estimated $11.4M sold.

Based on aggregated 13F filings for Q4 2013.